Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: Factors associated with response and suggestions for therapeutic sequence

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 8, 2013, Pages 1197-1205

  Campana, Davide ^a   Capurso, Gabriele ^b   Partelli, Stefano ^c,d,e   Nori, Francesca ^a   Panzuto, Francesco ^b   Tamburrino, Domenico ^d,e   Cacciari, Giulia ^a   Delle Fave, Gianfranco ^b   Falconi, Massimo ^d,e   Tomassetti, Paola ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

177Lu DOTATATE; 90Y DOTATOC; Neuroendocrine tumours; Radiotherapy; Somatostatin receptors; Therapeutic chemoembolization

Indexed keywords

ANTINEOPLASTIC AGENT; DOTANOC TOC GA 68; DOTATATE LU 177; DOTATOC Y 90; LUTETIUM 177; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SCINTISCANNING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DIARRHEA; DISEASE COURSE; DRUG SAFETY; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

AGED; FEMALE; HUMANS; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; SOMATOSTATIN; STOMACH NEOPLASMS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84879971280     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2402-2     Document Type: Article

References (28)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
2. Reubi JC, Laissue JA. Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci 1995;16:110-5.
3. Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab 2000;85:3882-91.
4. Arnold R, Benning R, Neuhaus C, Rolwage M, Trautmann ME. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion 1993;54 Suppl 1:72-5.
5. Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993;32:225-9.
6. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000;95:3276-81.
7. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63.
8. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30:207-16.
9. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941-5.
10. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610-6.
11. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147-56.
12. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30.
13. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010;40:78-88.
14. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416-23.
15. Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC; 2010.
16. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-62.
17. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
19. Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007;59:637-42.
20. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG, Eastern Cooperative Oncology Group. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005;23:4897-904.
21. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-71.
22. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13.
23. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
24. Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 2011;29:2372-7.
25. Panzuto F, Campana D, Fazio N, Brizzi MP, Boninsegna L, Nori F, et al.: Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. Neuroendocrinology 2012;96:32-40.
26. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 2008;19:903-8.
27. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-92.
28. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010;23:824-33.